Minimal residual disease (MRD) monitoring is an essential tool for risk group stratification in current treatment protocols for childhood acute lymphoblastic leukaemia (ALL). Although quantitative detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR ) gene rearrangements is currently considered to be the standard method, leukaemia fusion genes provide other possible targets for MRD follow-up, as already demonstrated in TEL/AML1-positive ALLs. We analysed and compared MRD levels quantified by BCR/ABL transcript detection and by the standard Ig/TCR-based method in 218 bone marrow specimens from 17 children with BCR/ABL-positive ALL. We found only a limited overall correlation of MRD levels as assessed by the two methods (correlation coefficient R 2 ¼ 0.64). The correlation varied among patients from excellent (R 2 ¼ 0.99) to very poor (R 2 ¼ 0.17). Despite identical sensitivity of the approaches, 20% of the samples were negative by the Ig/TCR approach whereas positive by the BCR/ABL method. We show that multilineage involvement is at least partly responsible for the discrepancy. Moreover, our data demonstrate that BCR/ABL monitoring enables better and earlier prediction of relapse compared to the standard Ig/TCR methodology. We conclude that BCR/ABLbased MRD monitoring of childhood ALL is a clinically relevant tool and should be performed in parallel with the standard Ig/ TCR follow-up.
Introduction
The chromosomal translocation t(9;22) resulting in the Philadelphia chromosome (Ph) is found in 3-5% of all children with acute lymphoblastic leukaemia (ALL). 1 Two types of this chromosomal rearrangement occur in childhood ALL. In the majority of ALL cases (B90%), the chromosome 22 breakpoint is located in the minor breakpoint cluster region (m-BCR), and translocation to the ABL gene on chromosome 9 generates the m-BCR/ABL fusion gene, encoding a 190 kDa hybrid protein (p190). The breakpoint within the Major breakpoint cluster region (M-BCR) of the BCR gene is typical for chronic myeloid leukaemia (CML) but it is less frequent (B10% of cases) in ALL. 2, 3 The latter variant results in the M-BCR/ABL fusion gene, encoding a 210 kDa hybrid protein, p210.
The presence of the BCR/ABL fusion gene in ALL is an adverse prognostic factor associated with a high risk of therapeutic failure. [4] [5] [6] Although the prognosis of BCR/ABL-positive childhood ALL is generally poor, certain heterogeneity in clinical outcomes reflecting the biological heterogeneity of this disease has been reported. 4, [7] [8] [9] The key components of the modern high-risk BCR/ABL-positive childhood ALL therapy are intensive chemotherapy (including bcr/abl kinase domain inhibitors) and haematopoietic stem-cell transplantation (HSCT).
Minimal residual disease (MRD) monitoring is used for the evaluation of treatment response, to stratify patients into risk groups on treatment protocols, and it also significantly influences clinical decisions in transplanted and off-protocoltreated patients. The highly significant prognostic value of MRD level at specific time points during treatment (both on frontline protocols and after HSCT) has been clearly documented in several studies. [10] [11] [12] [13] [14] [15] [16] Real-time quantitative polymerase chain reaction (RQ-PCR)-based detection of clonal immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements is the only standard method for MRD monitoring in childhood ALL. This method is applicable in virtually all (B95%) ALL patients. Use of the European BIOMED-1 and BIOMED-2 standardized protocols for target identification and the ESG-MRD-ALL (European Study Group for MRD detection in ALLFrecently renamed to ESLHO, European Scientific Foundation for Laboratory Haematology and Oncology) standardized principles for MRD quantification and interpretation provides an excellent basis for the substantial reproducibility of this method. [17] [18] [19] On the other hand, due to the necessity of individual target identification and RQ-PCR optimization, this MRD method is extremely labourious and time consuming and relatively expensive. Moreover, in a subset of patients, a clonal evolution of Ig/TCR targets during the follow-up period can hamper the accuracy of MRD monitoring. [20] [21] [22] [23] In Ph-positive (Ph þ ) ALL cases, quantitative detection of the BCR/ABL fusion transcript provides an alternative option for follow-up. MRD monitoring based on fusion transcript detection possesses some disadvantages, 24 but the substantial advantage of this method is the opportunity to use a universal system for fusion transcript identification and monitoring, which makes this method relatively easier, faster and cheaper than the Ig/TCR approach. We have previously shown that in TEL/AML1-positive childhood ALL, fusion transcript-based MRD monitoring is clinically relevant and closely correlates with the Ig/TCR approach. 25, 26 The clinical relevance of fusion transcript-based MRD monitoring in BCR/ABL-positive childhood ALL was shown in a study by Cazzaniga et al., 7 demonstrating that prospective qualitative monitoring of BCR/ABL by reverse transcription-PCR reveals the heterogeneity in treatment response and risk of therapy failure. However, there are no published data regarding quantitative BCR/ABL follow-up in childhood ALL and, importantly, no comparison of quantitative BCR/ABL fusion transcript detection and standard Ig/TCR-based MRD monitoring has been ever provided.
In our study we aimed to determine the correlation between two independent MRD approaches in BCR/ABL-positive childhood ALL. We retrospectively analysed 218 samples from 17 children with Ph þ ALL and compared MRD levels by quantitative detection of Ig/TCR and BCR/ABL fusion transcript. Our data show that there is only a limited correlation between both methods and a relatively high subset of samples with discordant MRD information and that multilineage involvement is at least partly responsible for the discrepancy. We demonstrate that parallel MRD monitoring based on BCR/ABL transcript detection brings additional clinically relevant information to Ig/TCR-based follow-up and, thus, should be preformed in all children with BCR/ABL-positive ALL.
Patients and methods

Patients and samples
A total of 17 children (6 girls and 11 boys, age 4-17 years) with Ph þ ALL diagnosed in the Czech Republic between 1994 and 2007 were enroled in our retrospective study. Depending on the time of diagnosis, they were treated according to one of four consecutive BFM-based treatment protocols. Of the 17 children, 13 suffered from one or more relapses during the treatment (bone marrow relapse: n ¼ 13; isolated central nervous system relapse: n ¼ 2; isolated testicular relapse: n ¼ 1), 4 patients are in the first complete remission (CR; median follow-up of these 4 patients is 62 months). Of the children, 15 underwent HSCT (8 in the first CR, 7 in the second CR). For the MRD analysis, 218 bone marrow (BM) follow-up samples were available. The informed consent of the patients' parents or guardians was obtained in all cases.
Cell processing, DNA and RNA extraction, reverse transcription Mononuclear cells from diagnostic and relapse BM/peripheral blood (PB) samples were isolated by Ficoll-Paque (density 1077 g/ml; Pharmacia, Uppsala, Sweden) density centrifugation. Follow-up samples were processed by erythrocyte lysis. Aliquoted cells were stored at À80 1C before DNA/RNA extraction.
Genomic DNA was isolated by one of the following methods: the QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany); BioRobot EZ1 with the EZ1 DNA Blood Kit (QIAGEN GmbH); ethanol precipitation from phenol phase after RNA isolation; the salting out method. 27 Total RNA was extracted using a modification of the method described by Chomczynski and Sacchi. 28 Total RNA was reverse transcribed into cDNA using MoMLV Reverse Transcriptase (Gibco BRL, Carlsbad, TX, USA) according to the manufacturer's instructions.
BCR/ABL RQ-PCR detection BCR/ABL and b2 microglobulin (b2M) transcript levels in the cDNA samples were determined by RQ-PCR in the LightCycler system (Roche Diagnostic GmbH, Basel, Switzerland) according to manufacturer's instructions. The b2M transcript was used as an endogenous control to normalize cDNA concentration and quality as described previously. 26 The BCR/ABL Major and minor variants were detected by two separate systems with identical reverse primers and hydrolysation probes but two different forward primers (ABL reverse primer: GGTTTGGGCTTCACACCATTC; probe: 6FAM-CCATTGTGAT TATAGCCTAAGACCCGGAGCTXT-PH; m-BCR forward primer: GCCCAACGATGGCGAGG; M-BCR forward primer: TTCCGCTGACCATCAATAAGG). The PCR amplification was carried out in 1 Â PCR buffer (supplied with Platinum Taq DNA polymerase) containing 200 mmol/l of each dNTP, 0.5 mmol/l of each primer, 0.2 mmol/l of probe, 5 mg of bovine serum albumin and 1 U of Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad, CA, USA) per reaction in a final reaction volume of 20 ml. The cycling conditions were 150 s at 95 1C followed by 45 cycles at 95 1C/3 s, 62 1C/10 s and 72 1C/5 s. The standard curves were generated using serial dilutions of plasmid calibrators containing the sequences of measured transcript. The standard curve parameters were obtained automatically by the LightCycler software using calculations of the second derivative maximum. Concentrations of the target (BCR/ABL) and control (b2M) were measured in each sample, and the relative copy number of the target (target level) was calculated as a ratio between BCR/ABL and b2M concentrations. Experiments were performed in duplicate, except for 12 samples where the RQ-PCR reactions were run just once due to a lack of cDNA material. Correlation of MRD levels between the Ig/TCR and BCR/ABL approaches did not differ significantly in these 12 samples compared to the rest of the sample cohort.
Ig/TCR detection
Rearrangements of immunoglobulin heavy chain (IGH ), immunoglobulin light chain kappa (IGK ) and T-cell receptors delta (TCRD), gamma (TCRG ) and beta (TCRB) were identified using single or multiplex PCR. 18,19. Quantification of clone-specific antigen-specific receptor gene rearrangements was performed using germline probes and reverse primers [29] [30] [31] [32] [33] as described previously. 13 The albumin gene was used to normalize DNA concentration and quality. 34 We monitored three Ig/TCR targets in 1 patient, two Ig/TCR targets in 13 patients and one Ig/TCR target in 3 patients. The highest Ig/TCR target level was used for MRD assessment.
MRD assessment
The ESG-MRD-ALL criteria for RQ-PCR sensitivity, quantitative range and MRD interpretation were applied to both Ig/TCR and BCR/ABL approaches. 17 The RQ-PCR sensitivity was at least 10 À4 for Ig/TCR and 10 transcript copies for BCR/ABL. Strict cutoff values for the minimal control gene/transcript concentrations were applied to eliminate samples with inadequate DNA/cDNA quality. The main cut off (1% of 'reference value') was applied to all samples. To preclude the possibility of false-negative results we applied an even stricter second cut off (10% of 'reference value') to the samples with immeasurable Ig/TCR or BCR/ABL MRD levels. The 'reference value' for the DNA experiments was the level of albumin assessed in 200 ng of buffy coat DNA. The 'reference value' for the cDNA experiments was set individually in each patient as a b2M concentration assessed in the diagnostic cDNA containing 10 5 copies of BCR/ABL transcript; this strict approach ensures comparable sensitivity of BCR/ABL quantitative monitoring up to the MRD level 10 À5 in all patients. The samples with a DNA/cDNA concentration under the cut-off values were excluded from further analysis. Thus, we refer to 17 diagnostic/relapse samples and 201 followup specimens. MRD in follow-up samples was expressed as a ratio of target level in a particular sample to target level in a diagnosis or relapse (in the 5 patients with unavailable material from diagnostic BM aspiration).
Cell sorting
In one of the recent cases with sufficient amount of material we were able to sort the BM cells from one of the follow-up samples according to the presence of surface antigens into three different subpopulations: malignant B-cell precursors (CD19 þ , CD20À, CD34 þ ), non-malignant B-lineage (CD19 þ , CD20 þ , CD34À, CD13À, CD14À) and myeloid cells (CD13 þ or CD14 þ , CD19À). The sorting was performed on high speed cell sorter FACS Aria (BD, San Jose, CA, USA).The purity of the sorted subpopulations was 499%.
Results
The BCR/ABL level in the diagnostic/relapse samples We detected m-BCR/ABL expression in all 17 patients and M-BCR/ABL in 3 cases, expressing both transcripts simultaneously. The relative m-BCR/ABL copy number in nine diagnostic BM samples from patients expressing only the m-BCR/ABL transcript ranged from 134 to 20,909, spanning 41.5 logs (Figure 1 ). The relative M-BCR/ABL copy number in three diagnostic samples from patients expressing both variants ranged from 3276 to 7453 spanning less than 0.5 log (Figure 1 ). The relative m-BCR/ABL copy number in diagnostic samples from these three patients ranged from 0.8 to 2.3, being on average 10 3 times lower than in patients expressing m-BCR/ABL only ( Figure 1 ). White blood cell (WBC) count, age, immunophenotype and blast proportion in BM showed no relation to the initial BCR/ABL level (data not shown). Due to the observed interpatient differences in initial BCR/ABL expression, the MRD level was expressed as a ratio of the target level in a particular follow-up sample to the target level in a diagnostic sample. This approach is analogous to ESG-MRD-ALL principles, where the diagnostic sample is assigned a value of 1 ( ¼ 100%). The M-BCR/ABL was used for MRD assessment in the followup samples of all patients expressing both BCR/ABL variants. In five patients expressing only m-BCR/ABL, we had no material from the diagnostic BM. In these patients, we used relapse as the reference value for MRD follow-up. The relative m-BCR/ABL copy number in these five relapse samples ranged from 820 to 6040, matching the range of the diagnostic samples (Figure 1 ).
Correlation of BCR/ABL-and Ig/TCR-based MRD The m-BCR/ABL transcript is present also in Ig/TCR-negative non-leukaemic cells
In one of the patients with m-BCR/ABL transcript and poor BCR/ ABL vs Ig/TCR correlation (UPN1092) we were able to analyse one of the early follow-up samples for the presence of clonal markers in three sorted cell populations: malignant B-cell precursors, non-malignant B-lineage and myeloid cells. As expected, the levels of both Ig/TCR targets (IGH and IGK) and m-BCR/ABL found in pure malignant B-cell precursor subpopulation were higher compared to the unsorted diagnostic sample. For the comparison of subpopulations the levels in the leukaemic cells were stated as 100%. Although the m-BCR/ ABL expression was high also in the non-malignant B-lineage and in myeloid cells (420% and 410% of the 'leukaemic cells expression', respectively) the level of both Ig/TCR markers was very low in non-malignant subpopulations (0.02-0.1%) and corresponded to the level of sort purity ( Figure 3 ). The Ig/TCR vs BCR/ABL ratio was 1.0 (malignant B-cell precursors), 0.005 (non-malignant B-lineage) and 0.004 (myeloid lineage).
The level of BCR/ABL transcript is better and earlier predictor of relapse than Ig/TCR Altogether, 14 relapses with at least 1 preceding BM sample occurred during the follow-up of our cohort. We aimed to assess the value of both MRD-monitoring approaches in terms of ) samples among all BM specimens taken 6 and 12 months before relapse. The distribution of the positive samples was significantly different. Although the majority of samples preceding relapse were BCR/ABL-positive (17/23 and 29/45 6 and 12 months before relapse) only a minority of samples were Ig/ TCR-positive (8/23 and 15/45, respectively). The non-equal distribution of the BCR/ABL and Ig/TCR-positive samples was statistically significant (Fisher's exact test, P ¼ 0.017 and P ¼ 0.0058 for the two time points). The difference was also substantial when only the last 1 (in total 14 samples) or the last 2 (27 samples) BM specimens before relapse were taken into account (BCR/ABL-positive, 10/14 and 20/27; Ig/TCR-positive, 4/14 and 7/27; P ¼ 0.057 and P ¼ 0.0009 for the last one and the last two samples, respectively). On the contrary, the distribution of MRD positivity in the BM samples taken more than 1 year before relapse was comparable using both approaches (P40.3 for samples taken between 1 and 2 years before relapse and also for all BM samples preceding relapse by 41 year).
Discussion
We present the first study evaluating the use of quantitative BCR/ ABL-based MRD monitoring in childhood ALL. Moreover, we show its direct correlation with the Ig/TCR-based approach, the only standard method for the MRD monitoring in ALL. We analysed quantitative levels of the BCR/ABL fusion transcript in 17 BM diagnostic/relapse samples and in 201 follow-up samples from patients with Ph þ ALL. The level of BCR/ABL transcript expression at the time of diagnosis of childhood ALL has not been studied so far. In a study by Yokota et al., 35 the initial levels of m-BCR/ABL in 11 adults with ALL differed by 0.56 orders of magnitude. Substantial differences in the levels of M-BCR/ABL between patients in specified stages of CML were also described (41.5 logs and 41 log in chronic phase and blast crisis, respectively) 36 as well as an increase in M-BCR/ABL expression level corresponding to disease progression from the chronic phase to the blast crisis of CML. 37 However, the significance of the different BCR/ABL expression levels between individual CML (at the same disease stage) and ALL patients remains unknown. In our cohort, the levels of m-BCR/ABL transcript at diagnosis varied significantly between patients, spanning 41.5 logs.
We report three patients with simultaneous expression of minor-and Major-BCR/ABL transcripts. In all of them, the quantitative level of M-BCR/ABL in the diagnostic sample was significantly higher than the level of m-BCR/ABL and remained dominant in all follow-up samples. Low levels of m-BCR/ABL transcript were also described in adult M-BCR/ABL-positive CML patients, where they are believed to arise through alternative splicing or missplicing of the Major variant. 38 The number of patients expressing both BCR/ABL variants in our BCR/ABL quantification in Ph þ ALL M Zaliova et al study was too small to draw any broad conclusions. However, our data show that all children with Ph þ ALL should be initially screened for both BCR/ABL variants, and in case they are expressed simultaneously, both transcripts should be analysed in all follow-up samples. In each particular follow-up sample, the dominant transcript should then be used for MRD assessment.
In our study, we assessed MRD by two independent methods: quantitative detection of the BCR/ABL transcript at the mRNA level and quantitative detection of Ig/TCR rearrangements at the DNA level. We applied ESG-MRD-ALL principles for MRD quantification to both approaches in an attempt to provide the highest possible reproducibility, objectivity and comparability. In our previous study, we compared these two approaches in a biologically distinct subtype of childhood leukaemiaFTEL/ AML1-positive ALL. 25 In that study we compared MRD levels assessed by Ig/TCR monitoring and by fusion transcript-based RQ-PCR in 117 samples from TEL/AML1-positive patients. We demonstrated an excellent correlation of the two methods in the TEL/AML1-positive ALL (R 2 ¼ 0.9032) with only o7% of samples differing by 41 log. In contrast to that study, we found only a limited overall correlation of both methods in BCR/ABLpositive cases (R 2 ¼ 0.6429) using exactly the same methodology as described in the TEL/AML1 report.
The distribution of discordant samples between BCR/ABLpositive patients was non-random. Although the concordance in some patients was excellent (for example, patient UPN861: R 2 ¼ 0.99, 13 samples), in most of the cases the correlation was unsatisfactory (the lowest concordance found in patients UPN1092: R 2 ¼ 0.17, 10 samples; UPN4: R 2 ¼ 0.35, 28 samples). Some patients were consistently MRD-positive by the BCR/ABL method and negative by the Ig/TCR approach during long period before relapse. In Figure 4 , the levels of MRD by both methods are shown for two such patients (Figures 4a  and b ) and for one patient with excellent overall correlation (Figure 4c ). Although our data suggested better correlation of M-BCR/ABL expression with the Ig/TCR approach (2/3 patients showed excellent correlation, R 2 ¼ 0.99 and R 2 ¼ 0.93), the low number of M-BCR/ABL-positive patients (n ¼ 3) precluded any reasonable conclusions.
During the follow-up of our patients we also examined 138 PB samples (data not shown). We found a significant discrepancy between the correlation levels in BM vs PB samples (PB: R 2 ¼ 0.5389). Our results demonstrate that leukaemic cells have lower BCR/ABL expression in PB compared to BM, despite being positive for clonal Ig/TCR markers in both compartments (data not shown). Thus, we strongly recommend preferential use of BM rather than PB specimens for BCR/ABL-based MRD monitoring and we report only to BM samples in this study.
Six of our patients received the specific BCR/ABL inhibitor, imatinib, during the follow-up period. Although this compound became a crucial component of CML treatment, publications analysing its role in the management of childhood ALL are so far extremely rare. 39 The correlation of the two analysed MRD methods is very similar in the 'imatinib' vs 'non-imatinib' BM samples and our data do not demonstrate any tendency to lower BCR/ABL expression in Ig/TCR-positive cells during the imatinib treatment. Prospective studies with imatinib in childhood ALL are in progress worldwide; these studies will definitely show whether imatinib has a specific effect on BCR/ABL expression and the correlation of the DNA vs mRNA-based MRD approach.
We consider the high frequency of BCR/ABL single positivity to be the most significant result of our study. Among all samples, 20% were BCR/ABL-positive and Ig/TCR-negative. There are several possible explanations of this discrepancy: (1) false BCR/ ABL positivity due to sample cross-contamination, (2) false Ig/ TCR negativity (for example, due to the subclonal Ig/TCR target or loss of Ig/TCR positivity during clonal evolution), (3) higher sensitivity of the fusion transcript-based method, (4) the presence of the BCR/ABL fusion in Ig/TCR-negative cells (for example, due to a multilineage BCR/ABL involvement) or (5) very high BCR/ABL expression in a very small cell population. Although we cannot completely rule out the reasons listed under points 1-3, we believe they are very unlikely explanations for the discrepancy between the two approaches. Sample crosscontamination is considered to be a general disadvantage of fusion transcript-based MRD monitoring, and to prevent this, we followed strict rules for sample processing. In some patients the BCR/ABL single positivity was present at a high level, and BCR/ ABL was continuously single-positive in many subsequent samples processed separately, over the course of years. Thus, we consider cross-contamination to be a highly improbable explanation of this phenomenon. In a majority of patients, we monitored X2 clonal Ig/TCR targets, and in all cases we repeated Ig/TCR rearrangement screening upon relapse of the disease. We found no loss of Ig/TCR target due to the clonal evolution in our cohort of patients. According to our experimental data, the sensitivity of both methods was identical. Moreover, in the patients with concordant results, the MRD data correlated well even at low levels.
We believe that both of the reasons listed as (4) and (5) could play a role in the overall unsatisfactory correlation of the two methods. Although multilineage/stem cell involvement has been proven in M-BCR/ABL-positive CML, there is still dispute about its role in BCR/ABL-positive ALL. The published studies usually refer to a limited number of patients and draw different conclusions, but at least in a subset of patients, multilineage involvement has been clearly demonstrated. [40] [41] [42] [43] [44] [45] We were able to analyse sorted cell populations from a follow-up sample in one of the recent cases with m-BCR/ABL expression (UPN1092) and we conclusively show that although the clonal Ig/TCR rearrangements are present only in the leukaemic cells, the BCR/ ABL fusion gene is found also in a subset of non-malignant B cells and in myeloid lineage. The data demonstrate that BCR/ ABL fusion as the first or early hit in leukaemogenesis arises in a progenitor cell with ability to differentiate into multiple haematopoietic lineages. This also opens an important question of a boundary between ALL and lymphoid blast crisis of CML; however, speculations about optimal treatment of these cases go beyond the scope of this study.
Different levels of BCR/ABL expression in various Ph þ subsets have been demonstrated as already mentioned above. The data show higher BCR/ABL expression in less mature cells in CML. 46, 47 Theoretically, these less mature cells (if also present in ALL cases) could cause a discrepancy in the BCR/ABL and Ig/TCR MRD approach by very high BCR/ABL expression in a limited subpopulationFperhaps potentiated by combination with Ig/TCR negativity.
The important question is: does BCR/ABL positivity in Ig/TCRnegative samples have clinical relevance, or is it a meaningless finding? Our data clearly show that the BCR/ABL positivity during the long-term follow-up is an earlier and better predictor of subsequent relapse of the disease compared to the Ig/TCR; thus, we believe BCR/ABL positivity reflects either the remaining leukaemic blast population, persistence of vulnerable cells with a significant leukaemic potential (leukaemic stem cells?) orF most likelyFcombination of both.
In conclusion, we strongly recommend monitoring of both MRD targets (BCR/ABL and Ig/TCR) in all Ph þ ALLs. The higher MRD levelFobtained by either approachFshould then be considered clinically relevant.
